What You Should Know:– Lunit, a provider of AI for cancer diagnostics, and Agilent Technologies Inc., a global leader in life sciences, have announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions. – The strategic partnership will combine Lunit’s AI technology with Agilent’s expertise in tissue-based companion diagnostics. The goal is to create advanced solutions that meet the demands of novel and complex biomarker assays in drug development. Accelerating Precision Oncology with AIThe collaboration will initially focus on co-developing AI-powered assays for use in research and clinical trials. The joint solutions will support pharmaceutical companies in companion diagnostic (CDx) product development, which will improve the precision of biomarker testing.